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Human primary malignant melanoma is often accompanied by a host response of infiltrating lymphocytes suggestive
of tumor antigen – induced immunity and correlated in some tumors with prognosis. Whereas metastatic melanoma
deposits typically are not inflamed and contain relatively few lymphocytes and dendritic immune cells, immunization
with autologous melanoma-cell vaccine may induce a clinical inflammatory response associated with mononuclear-
cell infiltration. In this study, we characterize immune responses to dermal and subcutaneous melanoma metastases
in dinitrophenyl (DNP)-pre-sensitized patients immunized with DNP-conjugated melanoma cells. Patients so treated
develop cutaneous delayed hypersensitivity responses to DNP-conjugated autologous mononuclear cells, and
approximately one-half show clinical evidence of inflammation and regression of metastases within 2-4 months.
Whereas pre-vaccination biopsies of metastatic melanoma failed to reveal significant infiltration by lymphocytes,
biopsies obtained after vaccination and coincident with clinical inflammation were markedly infiltrated preponder-
antly by T cells with a CD8þ phenotype. Clustering of these cells about individual degenerating melanoma cells in a
manner analogous to ‘‘satellitosis’’ was a consistent feature of this reaction. Enhanced expression of intercellular
adhesion molecule-1 (ICAM-1) and human leukocyte antigen (HLA)-DR by melanoma cells were invariably associated
with zones of T-cell infiltration, whereas diminished or absent expression was observed in relatively unaffected
regions of tumors. Numerous HLA-DRþ , CD4þ , CD1, Leu-1 dendritic cells were also associated with zones of early
T-cell infiltration. These data indicate that clinical inflammation and regression of metastatic melanoma induced by
autologous melanoma-cell vaccine involves activated T cells with cytotoxic - suppressor phenotype and dendritic cells
putatively capable of local antigen presentation. ICAM-1 upregulation on melanoma cells is a likely mediator of ligand
interaction between infiltrating T cells and target cells in this model of antigen-induced host antitumor response.
Structural alterations identified in this setting (e.g., tumor cell satellitosis) may provide additional insight into
identifying features of naturally occurring host immune responses to primary cutaneous melanomas. J Invest
Dermatol 100:335S–341S, 1993
A notion central to the seminal concept of tumor progression of
Clark is that developmental evolution of neoplastic cells may be
halted by protective host immune mechanisms. Human malig-
nant melanoma has been the subject of intense scrutiny
concerning its capability to provoke host immune responses [1].
There is obvious significance to the potential to recapitulate this
phenomenon therapeutically. Primary melanoma in early phases
of growth frequently is characterized by partially successful host
immune reactions that contribute to color variegation and border
irregularity [2]. More advanced primary tumors may evoke
immune responses at deepest points of dermal invasion. In such
instances, quantification of tumor-infiltrating lymphocytes (TILs)
may represent a significant independent prognostic variable [3].
The local and systemic mechanisms that account for immune
responses directed against melanoma cells are incompletely
understood. From a practical viewpoint, little is known concern-
ing structural details of immunologic regression resulting from
antigen-specific effector-target cell interactions.
Extrapolation from established experimental systems of effec-
tor-target-cell interactions, such as acute graft-versus-host dis-
ease, suggests that apposition of effector cells of cytotoxic
phenotype to degenerating target cells is a characteristic
morphologic feature of antigen-directed destructive immune
responses [4,5]. This phenomenon, termed ‘‘satellitosis’’ may be
observed in certain primary melanomas putatively undergoing
immune regression (Fig 1). Until now, experimental model
systems to determine whether this histology correlates with
antigenic phenotypes characteristic of melanoma-induced cyto-
toxicity have been lacking.
We recently studied clinical and immunologic responses in
human melanoma metastases, which ordinarily do not elicit
significant host lymphoid infiltration, after administration of
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autologous melanoma vaccine. This approach is based on pre-
administration of cyclophosphamide (CY) to heighten host
responses [6–10] to tumor-associated antigens [11–15] to which
cancer patients appear to develop immunologic tolerance
[16–23]. In clinical trials, it has been shown that the administra-
tion of CY prior to injection of autologous tumor vaccine can
induce delayed-type cutaneous hyper-sensitivity (DTH) to auto-
logous tumor cells and, sometimes, to regression of metastatic
tumors [24]. To further augment DTH to autologous tumor
antigens, the vaccine we used was conjugated to dinitrophenyl
(DNP), which is known to enhance cell-mediated immunity to
tumor-associated antigens [25–28]. In clinical trials using this
strategy, it was recently demonstrated that 14 of 24 patients so
treated exhibited immune-mediated anti-tumor responses direc-
ted against dermal and subcutaneous metastases [29,30].
In this report, we characterize the phenotype of immune
responses to melanoma metastases in patients clinically respond-
ing to DNP-conjugated autologous melanoma vaccine to better
understand the structural and antigenic details of host-mediated
immune regression. Our data suggest that satellitosis involving T
cells with a suppressor-cytotoxic phenotype is characteristic of
immune regression in melanoma induced by this form of therapy.
Moreover, these interactions are associated with dendritic
immune cell proliferation/infiltration and intercellular adhesion
molecule-1 (ICAM-1) induction in responding tumors.
MATERIALS AND METHODS
General Experimental Design In the initial treatment protocol, 24
patients with metastatic melanoma were given vaccine consisting of
autologous, cryopreserved, irradiated tumor cells conjugated to
DNP. All patients had at least one superficial metastasis in skin or
subcutaneous tissue that was directly observable and easily biopsied.
Patients were contact sensitized to the hapten by topical application
of dinitrofluorobenzene (DNFB) 3 d following low-dose (300mg/M2)
intravenous CY. Two weeks later, and subsequently every 28 d,
patients were injected intradermally on the upper arm with DNP-
haptenized melanoma cells mixed with bacille Calmette-Gue´rin as
adjuvant. CY was administered 3 d before each vaccine injection.
Skin testing with DNP-conjugated peripheral blood mononuclear
cells (MNC) revealed induction of DTH responses to DNP-
conjugated MNC in 22 of 24 patients after DNFB sensitization,
without DTH to MNC alone or conjugated to a non-cross-reactive
hapten, TNP. Between 2 and 4 months after initiation of DNP-
vaccine therapy (average two to four injections), 14 of 24 patients
developed erythema, warmth, and tenderness of metastatic tumors
and overlying skin. In 10 patients, one or more biopsies were
obtained for immunohistochemical analysis of inflammatory cells,
activation antigens, and adhesion molecules. In five patients,
biopsies were obtained prior to vaccination and subsequent to
vaccination at the time of peak clinical inflammatory response. In
addition to qualitative immunophenotypic evaluation, pre-vaccina-
tion and post-vaccination melanoma specimens from four patients
were also evaluated by computer-assisted image analysis to
determine the relative number of labeled T cells infiltrating tumors
(6,463–18,534 cells evaluated/lesion).
Clinical and Vaccination Protocol We treated 24 patients with
metastatic, surgically incurable melanoma, all of whom had at least
one metastasis in skin, subcutaneous tissues, or lymph nodes that
was directly observable and easily biopsied. Informed consent was
obtained. The patients were sensitized to DNP by topical application
of 1% DNFB in acetone corn oil on two consecutive days. Intra-
venous CY (300mg/M2) was administered 3 d before sensitization.
Figure 1. Morphologic characteristics of lymphoid response to primary malignant melanoma. Putative advanced inflammatory regression (A) is often
characterized by a zone of lymphocytes (L) and residual melanoma cells (arrows) bordered by lamellar collagen deposition in which pigment-laden
macrophages (P) are entrapped. Melanoma cells within the epidermal layer (EPI) are typically spared. Presumed earlier stages of TIL response are characterized
by clustering of rare (B) or numerous (C) lymphocytes about individual melanoma cells (arrows) in a manner similar to satellitosis, as classically described in
experimental graft-versus-host disease. Pronounced MNC response to a small dermal island of melanoma cells (D) is associated with lymphoid infiltration (larger
arrow) and tumor cell necrosis (small arrows). (A, magnification60; B–D, magnification200.)
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Two weeks later, patients were again given CY, followed 3 d later
by injection of DNP-conjugated melanoma vaccine; CY and DNP
vaccine were repeated every 28 d. The vaccine consisted of
10–25 106 cryopreserved, autologous, irradiated (2500 R), DNP-
conjugated melanoma cells prepared as previously described [31]
and mixed with bacille Calmette-Gue´rin. DNP conjugation was
performed by the method of Miller and Claman [32]. Patients were
tested for cell-mediated immunity to hapten-modified cells by skin
testing with DNP-conjugated peripheral blood MNC.
Biopsy Selection Initial T-cell antigen screening of 54 excisional
biopsies of metastatic melanomas from 24 patients pre-vaccination
and post-vaccination revealed inflammatory infiltrates to be re-
stricted to post-vaccination lesions undergoing clinical induration,
erythema, and enlargement (n¼ 14). Of these, four were excluded
because of the presence of zonal necrosis (a potential source of
secondary, non-specific inflammatory reactions) or the presence of
tumor within subcutaneous lymph nodes. As anticipated, cells
infiltrating extensively necrotic tumors expressed predominantly
histiocytic markers (CD15), and cells infiltrating nodal metastases
were predominantly of the CD4 subset and were not associated with
individual cell necrosis, human leukocyte antigen (HLA)-DR
induction, or satellitosis. Of the 10 remaining cases, five had at
least one pre-biopsy and post-biopsy sample, permitting assessment
of evolution of inflammation related to vaccination. The post-
vaccination specimens were obtained 2–4 months after initiation of
vaccine treatment, at points of maximum clinical inflammatory
change.
The number of inflamed tumors in a single patient ranged from 1
to more than 100 [33]. In patients with multiple superficial
metastases, 25–100% of observable lesions became inflamed.
Immunocytochemistry Each tissue specimen was subdivided into
1-mm - thick slabs and placed in Michel’s medium for transport
and temporary storage. Samples were washed in phosphate-buffered
saline (pH 7.4) (PBS), snap-frozen in liquid nitrogen, and cryostat
sectioned at 5-mm intervals. For comparative assessment of
proportions of inflammatory cells expressing certain epitopes,
adjacent tissue sections were studied to minimize artifact resulting
from local variation in cell number. Monoclonal antibodies used for
initial screening and detailed analyses are enumerated in Table I.
Labeling was obtained using an avidin-biotin-peroxidase com-
plex system (Vector Laboratories, Inc., Burlingame, CA) and 3,30-
diaminobenzidine as a chromagenic substrate. Briefly, tissue
sections were acetone fixed for 10min at 41C, and primary antibody
(or appropriate, isotype-specific irrelevant controls) (dilution range
1: 50–1:200) was placed over each tissue section and incubated in a
humidified chamber for 30min at room temperature. After thorough
rinsing with PBS, sections were overlayed with biotinylated anti-
mouse anti-serum (1:200) for 30min. After washing, avidinbiotin-
peroxidase complex was added at a concentration of 1:100 for
45min. Subsequent to thorough PBS rinse, sections were incubated
with 3,30-diaminobenzidine and 3% H2O2 in PBS and counter-
stained lightly with hematoxylin. Replicate sections were prepared
for each experimental condition for evaluation of cellular infiltrates
in routine paraffin sections.
Image Analysis Quantitative analysis of Leu-1þ cells was performed
on an image-analysis system consisting of a central computer (Sony
Communications Products Company, Park Ridge, NJ), color video
monitor (Mitsubishi), video camera (Southern Micro Instruments,
Inc., Atlanta, GA), and Olympus BH-2 light microscope. Pre-
treatment and post-treatment biopsy specimens from four individuals
Table I. Monoclonal Antibodies Used in This Study
Sourcea Antibody Reactivity
Bectin Dickinson Leu-1 CD5 (mature T cells)
Leu-2 CD8 (cytotoxic-suppressor
T cells)
Leu-3 CD4 (helper-inducer T cells;
macrophages)
Leu-6 CD1 (Langerhans cells)
Leu-7 Some cytotoxic T;
natural killer. (NK) cells
Leu-11 CD16 (Fc immunoglobulin G
receptor on NK cells
and neutrophils)
Leu-M1 CD 15 (monocytes)
Anti-HLA-DR Class II molecules on B cells,
g-interferon-stimulated cells
Coulter Corp. NKH-1 CD56 (NK cells)




Dako Corp. TAC Interleukin-2 receptor
ICAM-1 Intercellular adhesion molecule-1
(lymphocyte function associated
antigen-1 ligand)
aBectin Dickinson Immunocytometry Systems, Mountain View, CA;
Coulter Immunology, Hialeah, FL; Dako Corp., Carpinteria, CA.
Figure 2. Quantification of Leu-1þ TILs in metastatic melanomas before
(solid bars) and after (hatched bars) autologous DNP-conjugated melanoma
vaccine (n¼ 4; p¼0.04, 0.05, 0.005, and 0.03 for patients 1–4, respectively).
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were analyzed with cell-counting software (Southern Micro Instru-
ments, Inc.).
This system used 256 gray-scale values (GSV) from 0 to 255
(0¼ black, 255¼white), with the range between black and white
subdivided on the basis of relative shades of gray. The working area
on the video screen was 466 466 pixels (which represented square
meters after calibration), generating 217,516 pixels/field. The system
applied a GSV to each pixel.
Computer-assisted adjustment to GSV limits enabled segmenta-
tion of cells to be counted on the basis of color. Leu-1þ cells were
dark brown and therefore had lower GSV than Leu-1 cells, which
were light blue. Calibration was performed to ‘‘teach’’ the computer
the number of pixels occupied by a single cell of average area. To
determine the number of cells in the field of interest, the total
number of segmented pixels on the screen was divided by the
calibrated reference pixel count. This measurement was performed
to count both Leu-1þ cells and the total number cells in each field.
The accuracy of this method was confirmed by manual counting of
positively labeled cells/500 tumor cells in selected specimens with
concordance between 5 and 7%. Differences in the pre-vaccination
and post-vaccination number of infiltrating Leu-1þ cells for each
patient were evaluated for significance using the two-tailed paired
t test.
RESULTS AND DISCUSSION
Metastatic Melanoma—Pre-Treatment Biopsies of metastatic
melanoma demonstrated malignant cells within the dermis and
subcutis, with cytologic features compatible with their known
primary malignant melanomas. No specimens showed evidence
of significant tumor infiltration by lymphocytes, and immuno-
histo-chemistry revealed numerous fields devoid of T cells (Leu-1þ
cells) (Figs 2 and 3A). Computer-assisted image analysis revealed
between 54 and 421 Leu-1þ cells/10,000 tumor cells in four pre-
treatment biopsies (Fig 2) (a fifth case was excluded owing to
substantial cellular pigmentation impairing discrimination of
immunolabeled inflammatory cells). Only rare HLA-DRþ den-
dritic cells were present with tumor nodules, and tumor cells
expressed HLA-DR and ICAM-1 focally and weakly. These
findings are consistent with the paucity of lymphoid inflammatory
infiltration typically observed in metastatic melanoma deposits
[34,35] and with experimental evidence indicating that cell lines
derived from metastatic melanoma, in contrast to early primary
lesions, fail to induce autologous T-cell proliferation [36,37].
Metastatic Melanoma—Post-Treatment In contrast to pre-
treatment biopsies, all specimens of metastatic melanoma
(post-treatment, n¼10) were heavily infiltrated by HLA-DRþ
and Leu-1þ T cells (Fig 2 and Fig 3B). Histologic analysis (Fig 3C)
Figure 3. Immunophenotypic characterization of TIL response in lesions showing clinical inflammation-regression after autologous vaccination. Characteristic
fields of metastatic melanoma from a single patient stained with Leu-1 before (A) and after (B) vaccination. Routine microscopy (C) reveals brisk TIL response
with foci where lymphocytes surround individual tumor cells (M) in a manner analogous to satellitosis (inset). Subsetting of the TIL response in adjacent
tissue sections revealed the majority of cells to be CD8þ (D) and the minority to be CD4þ (E). Clustering of TILs about melanoma cell(s) (D and E, arrows)
was consistently produced by only the CD8þ subset (D). (A, B, D, E, magnification100; C, magnification 200; C inset, magnification 400.)
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demonstrated small lymphoid cells diffusely infiltrating among
large, anaplastic melanoma cells in a pattern identical to that
described for TILs in primary melanoma [3]. Degenerative
melanoma cells were frequently surrounded by peripheral
clusters of lymphocytes in a pattern similar to satellitosis, as
described in acute graft-versus-host disease [4,5] (Fig 3C, inset).
Computer-assisted image analysis (Fig 2) confirmed the difference
in the number of TILs between pre-treatment specimens (54–421
Leu-1þ cells/10,000 cells) and post-treatment specimens
(1160–2559 Leu-1þ cells/ 10,000 cells) (p¼ 0.03–0.005).
Immunophenotypic analysis for T-cell subclasses in adjacent
tissue sections revealed that the majority of infiltrating T cells
Figure 4. Immunophenotypic characterization of ICAM-1 expression and of dendritic cells in lesions showing clinical response after vaccination. (A,B) Adjacent
sections of subcutaneous melanoma, one stained with Leu-1 (A) and the other stained for ICAM-1 (dotted line demarcates junction between stroma above
and tumor cells below). Zone of most pronounced infiltration by small T lymphocytes (A, upper third of tumor nodule) corresponds to most intense ICAM-1
expression by larger tumor cells (B). Less pronounced ICAM-1 expression (B, lower two-thirds of tumor nodule) corresponds to diminished TIL response (A, lower
two-thirds of tumor nodule). Staining for HLA-DR in adjacent sections of the upper third (B, upper arrow), middle third (B, middle arrow), and lower third
(B, lower arrow) is shown in C–E. Note the zones of diffuse class II expression by larger tumor cells and dendritic cells (C) and exclusive expression by numerous
(D) and less numerous (E) dendritic cells. These zones correlate directly with areas of most pronounced (top) to least pronounced (bottom) Leu-1þ T-cell
infiltration (A) and ICAM-1 expression (B). Dendritic cells from zones represented in C and D expressed CD4 (F), although the majority were negative for
Leu-Ml (G). (A and B, magnification 60; C–E, magnification200; F and G, magnification 100.)
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were CD8þ (Fig 3D), and a minority were CD4þ (Fig 3E ).
Moreover, peripheral aggregation of CD8þ T cells about
melanoma cells in a pattern corresponding to the satellitosis
typical of routine histologic preparations (Fig 3C, inset) was
frequently observed (Fig 3D). Only rare cells were Leu 7þ or Leu
11þ , indicating that natural killer (NK) cells do not account for a
significant proportion of the TIL response induced by autologous
vaccine. The majority of TILs did not express immunoreactive
interleukin-2 (IL-2) receptors using the Tac antibody, an observa-
tion in keeping with previously reported fluorescence-activated
cell sorting analyses of inflamed tumors post-vaccination [33] and
with our observations using this labeling system in experimental
cutaneous DTH [38]. Whether this represents an artifact of
antibody used, sensitivity of immunohistochemical localization,
timing of biopsy, or the result of receptor saturation by IL-2,
remains to be determined. Because TAC antibody labels only the
a-chain of the IL-2 receptor, studies using recently described
monoclonal reagents to the b-chain of the IL-2 receptor [39] are
now clearly indicated. In vivo, TILs were recently shown to be of
the CD3þ CD8þ phenotype, with an oligoclonal (rather than
polyclonal) pattern of T-cell receptor gene rearrangement [40].
Cytotoxicity against melanoma cells was recently demonstrated
to reside in cloned populations of CD8þ T cells that recognize
autologous tumor cells through the T-cell receptor and in an HLA
class I-restricted manner [41].
It was not possible to reliably segregate the minority
population of CD4þ TILs into 4B4þ (helper-inducer) and
2H4þ (suppressor-inducer) subgroups because tumor cells
demonstrated apparent expression of the CD45RO epitope
(defined by 4B4 antiserum), precluding comparative enumeration
of associated labeled lymphoid elements. Occasional lymphoid
cells were 2H4þ , however, representing infiltration of tumors by
a suppressor- inducer CD4þ subset that may be impaired by CY,
accounting partially for its immunoenhancing effect [42].
Presumed early T-cell infiltration of metastatic melanoma at
the periphery of nodules was spatially associated with tumor cell
ICAM-1 expression (Fig 4A,B). As in experimental cutaneous
DTH responses in human interfollicular epidermis [38,43], T-cell
migration into melanoma nodules was invariably associated with
enhanced expression of melanoma cell ICAM-1, indicative of
possible g-interferon effect. ICAM-1 regions of tumor were never
infiltrated by T cells in excess of numbers seen in pre-vaccination
specimens. These observations raise the possibility that interac-
tion between TILs and melanoma cells may be partially mediated
by ICAM-1/lymphocyte function-associated antigen-1 ligand
interactions. Although such interaction would potentially facil-
itate efficacy of immune responses, it has also been suggested that
ICAM-1 expression by melanoma cells could enhance ‘‘passen-
ger’’ dissemination via heterotopic attachment between malig-
nant cells and leukocytes actively trafficking across vessel-tissue
interfaces [44].
In zones of maximal ICAM-1 immunoreactivity (Fig 4C ),
melanoma cells strongly expressed HLA-DR, whereas areas of
minimal ICAM-1 staining (Fig 4D ) revealed HLA-DR expression
only by infiltrating CD1 dendritic cells. ICAM-1 zones of tumor
(Fig 4E ), which typically were devoid of infiltrating T cells,
displayed fewer, less intensely stained dendritic HLA-DRþ cells.
The majority of dendritic cells infiltrating vaccine-treated
melanomas were CD4þ (Fig 4F ), although these cells were
clearly separable morphologically and antigenically from more
rounded CD5þ T cells, which also may express class II molecules
on activation (Fig 4G). The HLA-DRþ , CD1, and CD4þ
phenotypes of these dendritic cells suggests that they belong to
the family of dermal dendritic immune cells, as originally
described in 1985 by virtue of differential immunoreactivity for
antibodies to certain b2-microglobulin glycoproteins shared by
Langerhans cells and endothelial cells [45]. Recently, dermal
‘‘dendrocytes’’ exhibiting positivity for the fibrin-stabilizing
factor, factor XIIIa, have been characterized [46]. These cells
probably represent a congruent population of dermal dendritic
immune cells. It is intriguing to speculate that some of these
dendritic cells may be responsible for fibrin–fibronectin poly-
merization, antigen presentation, or cytokine production that
augments the T-cell migration or activation directed against
melanoma cells after immunization.
The findings in this study support the concept that immuno-
logic responses to metastatic malignant melanoma after admin-
istration of autologous, hapten-conjugated vaccine involve
infiltrative lymphoid populations predominantly of the CD8þ
phenotype. Tumors so affected may demonstrate ICAM-1 and
HLA-DR expression, presumably induced by g-interferon, a
lymphokine that has been shown to regulate T-cell responses
to melanoma in vitro [34]. Moreover, HLA-DRþ , CD4þ , and
CD1 dendritic immune cells appear integral to T-cell infiltration
of melanomas after autologous vaccination. These observations in
a relevant clinical model of antigen-induced melanoma regres-
sion may aid in understanding naturally occurring structural
alterations typical of tumor-directed host immunity in primary
melanomas, as well as the cellular interactions that underpin
efficacy of melanoma immunotherapy in responsive recipients.
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